Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 XU Chunhua , CHI Chuanzhen , YUAN Qi , WANG Wei , WANG Yuchao , ZHANG Qian

Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R.China;

Corresponding?author：

XU Chunhua, Email: xuchunhua_nj@163.com

Keywords：

Chronic obstructive pulmonary disease; Acute exacerbation; Copeptin

DOI：

10.7507/1671-6205.201612029

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical value of plasma copeptin in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Ninety patients with AECOPD admitted between October 2013 and November 2015 were recruited as an AECOPD group, and 40 healthy subjects underwent physical examination simultaneously were recruited as a control group. According to patient history and severity, the AECOPD patients were divided into 3 groups: grade Ⅰ group (25 cases), grade Ⅱ group (45 cases) and grade Ⅲ group (20 cases). Plasma copeptin level was measured by enzyme-linked immunosorbent assay (ELISA). The changes of copeptin, the total counts of white blood cells (WBC), and C-reactive protein (CRP) of the AECOPD patients were compared before and after treatment. Then the correlations between plasma levels of copeptin and severity of AECOPD were evaluated. Results The plasma level of copeptin in the AECOPD group was higher than that in the control group [(16.4±5.2) pmol/L vs. (5.7±2.8) pmol/L, P<0.05), and gradually increased with the severity of AECOPD. For the AECOPD patients both before and after treatment, the copeptin concentrations were positive correlated with the plasma CRP concentrations and the total counts of WBC in blood (both P<0.05). Conclusions The plasma levels of copeptin gradually increase with the severity of AECOPD. The changes of plasma copeptin may be as an indicator for the severity of AECOPD.

Citation： XU Chunhua, CHI Chuanzhen, YUAN Qi, WANG Wei, WANG Yuchao, ZHANG Qian. Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2017, 16(4): 324-326. doi: 10.7507/1671-6205.201612029 Copy

1.	Gold Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2013) [EB/OL]. [2013-11-20]. Available at http://goldcopd.org.
2.	榮蓉. 慢性阻塞性肺疾病急性加重期下呼吸道感染細菌特點及耐藥性分析. 國際呼吸雜志, 2015, 35(15): 1149-1151.
3.	謝嵐, 毛欣, 李建剛, 等. 降鈣素原在慢性阻塞性肺疾病急性加重期抗生素使用中的指導意義. 中國呼吸與危重監護雜志, 2013, 12(3): 237-239.
4.	Morgenthaler NG, Mailer B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor is elevated in hemorrhagic and septic shock. Shock, 2007, 28(2): 219-226.
5.	Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 2007, 131(4): 1058-1067.
6.	Neuhold S, Huelamann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52(4): 266-272.
7.	劉海玉, 周國平, 李東峰, 等. 血清和肽素、降鈣素原及超敏 C-反應蛋白對腦出血患者肺部感染早期診斷及預后判斷的價值. 中華醫院感染學雜志, 2016, 26(23): 5410-5412.
8.	趙玉清, 袁桂莉, 張進順, 等. 和肽素聯合 N 末端 B 型利鈉肽原評估慢性心力衰竭患者預后的價值. 中國循環雜志, 2014, 29(4): 275-278.
9.	吳鑫虎, 邱俏檬, 洪廣亮, 等. 血清和肽素對膿毒癥早期診斷及預后評估的臨床意義. 中國急救醫學, 2012, 32(7): 589-591.
10.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
11.	慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(2014 年修訂版). 國際呼吸雜志, 2014, 34(1):1-11.
12.	Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin North Am, 2013, 33(1): 95-115.
13.	Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23(6): 932-946.
14.	Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc, 2006, 54(2): 345-353.
15.	Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006, 91(11): 4381-4386.
16.	Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis, 2004, 61(2):112-116.
17.	Christ-Crain M, Mailer B. Biomarkers in respiratory, tract infections:diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
18.	趙云峰, 林勇, 張衛國. 社區獲得性肺炎患者血清合肽素測定的臨床意義. 中華結核和呼吸雜志, 2009, 32(12):911-914.
19.	Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52(1): 112-119.
20.	曾憲威. 降鈣素原和 C-反應蛋白水平及白細胞計數聯合檢測對呼吸道感染的診斷價值. 中華實驗和臨床感染病雜志(電子版), 2016, 10(1): 69-72.

1. Gold Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2013) [EB/OL]. [2013-11-20]. Available at http://goldcopd.org.
2. 榮蓉. 慢性阻塞性肺疾病急性加重期下呼吸道感染細菌特點及耐藥性分析. 國際呼吸雜志, 2015, 35(15): 1149-1151.
3. 謝嵐, 毛欣, 李建剛, 等. 降鈣素原在慢性阻塞性肺疾病急性加重期抗生素使用中的指導意義. 中國呼吸與危重監護雜志, 2013, 12(3): 237-239.
4. Morgenthaler NG, Mailer B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor is elevated in hemorrhagic and septic shock. Shock, 2007, 28(2): 219-226.
5. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 2007, 131(4): 1058-1067.
6. Neuhold S, Huelamann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52(4): 266-272.
7. 劉海玉, 周國平, 李東峰, 等. 血清和肽素、降鈣素原及超敏 C-反應蛋白對腦出血患者肺部感染早期診斷及預后判斷的價值. 中華醫院感染學雜志, 2016, 26(23): 5410-5412.
8. 趙玉清, 袁桂莉, 張進順, 等. 和肽素聯合 N 末端 B 型利鈉肽原評估慢性心力衰竭患者預后的價值. 中國循環雜志, 2014, 29(4): 275-278.
9. 吳鑫虎, 邱俏檬, 洪廣亮, 等. 血清和肽素對膿毒癥早期診斷及預后評估的臨床意義. 中國急救醫學, 2012, 32(7): 589-591.
10. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
11. 慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(2014 年修訂版). 國際呼吸雜志, 2014, 34(1):1-11.
12. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin North Am, 2013, 33(1): 95-115.
13. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23(6): 932-946.
14. Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc, 2006, 54(2): 345-353.
15. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006, 91(11): 4381-4386.
16. Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis, 2004, 61(2):112-116.
17. Christ-Crain M, Mailer B. Biomarkers in respiratory, tract infections:diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
18. 趙云峰, 林勇, 張衛國. 社區獲得性肺炎患者血清合肽素測定的臨床意義. 中華結核和呼吸雜志, 2009, 32(12):911-914.
19. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52(1): 112-119.
20. 曾憲威. 降鈣素原和 C-反應蛋白水平及白細胞計數聯合檢測對呼吸道感染的診斷價值. 中華實驗和臨床感染病雜志(電子版), 2016, 10(1): 69-72.

Chinese Journal of Respiratory and Critical Care Medicine

Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content